Los puntos clave no están disponibles para este artículo en este momento.
Combination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients.
Atkins et al. (Tue,) studied this question.